The Latest

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire here.

    Intellectual property is the foundation of the drug industry’s business model. This database will track key patent expiry dates for 30 top-selling medicines.

    Updated May 13, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Intra-Cellular depression drug succeeds in second late-stage study

    The results position the company to unlock what’s believed to be a multibillion-dollar sales opportunity for Caplyta, which is already used to treat schizophrenia and bipolar disorder. 

  • Two researchers in safety goggles and lab coats work in a lab.
    Image attribution tooltip
    Permission granted by Kevin Trimmer/Ascidian Therapeutics
    Image attribution tooltip

    Roche partners with RNA editing biotech Ascidian

    While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

    Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.

  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Takeda drug for rare types of epilepsy misses goal in late-stage trial

    Called soticlestat, the drug had seemed promising in earlier studies for people with Dravet and Lennox-Gastaut syndrome, enough to persuade Takeda to take on full rights to the drug.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Eleven private biotech companies have been acquired through May, putting 2024 on pace to be a particularly strong year for startup M&A.

    Updated May 29, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Syncona melds two gene therapy biotechs for better shot at new nervous system treatments

    The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.

  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie joins in latest gastrointestinal drug chase

    Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.

  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Radiopharma drugmaker Telix pulls US IPO plans

    The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

    The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Alumis outlined plans for an offering that, if successful, would be the third by an immune drug developer this year.

    Updated June 9, 2024
  • A headshot of Peter Emtage, CEO of Santa Ana Therapeutics.
    Image attribution tooltip
    Permission granted by Versant Ventures
    Image attribution tooltip
    Emerging biotech

    Versant debuts biotech working on ‘anger management for the immune system’

    Investor enthusiasm for precision immunology medicines is providing a tailwind for Santa Ana Therapeutics, a new startup backed by Versant, GV and a16z, among others.

  • The U.S. Supreme Court is seen in spring through the branches of a tree.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    Supreme Court preserves access to abortion pill in unanimous ruling

    The high court said the plaintiffs’ “desire to make a drug less available to others” did not give them standing to challenge the FDA's expansion of mifepristone’s approval.

  • a nurse gives a vaccination to a woman sitting in a chair
    Image attribution tooltip
    Joe Raedle/Getty Images via Getty Images
    Image attribution tooltip

    Moderna says next-gen COVID shot effective in study

    Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.

  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    Pfizer gene therapy for Duchenne fails to meet goals of key trial

    The negative results from the Phase 3 study, called Ciffreo, come a little more than a month after Pfizer said a patient died in another trial of the gene therapy.

  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Pla2Na via Getty Images
    Image attribution tooltip

    Foresite, a biotech venture firm, reloads with $900M fund

    Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.

  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    Obesity drugs

    Flagship taps startup to hunt for obesity drugs that might interest Pfizer

    The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

    Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip

    Ultragenyx, Mereo drug reduces fractures in bone disorder study

    New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.

  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    ADCs are in focus. Here’s where AstraZeneca, AbbVie hope to take the field next.

    Newer components and drug combinations could expand use of the targeted cancer medicines, according to company executives.

  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    Lilly Alzheimer’s drug gets unanimous backing of FDA panel

    The expert committee's twin 11-0 votes tees up donanemab for U.S. approval later this year and a market showdown with Leqembi.

    Updated June 11, 2024
  • Brain scans of a person with Alzheimer's are seen in this conceptual image.
    Image attribution tooltip
    digicomphoto via Getty Images
    Image attribution tooltip
    New Alzheimer's drugs

    Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say

    After an FDA panel backed the experimental Lilly drug, Wall Street analysts see its likely clearance as benefiting Eisai and Biogen’s rival Leqembi.

  • An illustration of human liver anatomy against a stylized background.
    Image attribution tooltip
    Rasi Bhadramani via Getty Images
    Image attribution tooltip

    Ipsen drug for rare liver disease approved by FDA

    The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.

  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna says combination flu, COVID shot succeeds in study

    Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.